Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ranbaxy to Market Levofloxacin, Ofloxacin in Singapore: Daiichi Sankyo
March 14, 2011
- Takeda Licenses PDE1 Inhibitors from ITI
March 14, 2011
- Japan's Biosimilars Market Has Strong Growth Potential: Mr George of Sandoz
March 14, 2011
- Terumo Acquires CaridianBCT for US$2.6 Bil.
March 14, 2011
- Memantine, Galantamine Enter NHI Price List
March 14, 2011
- EC to Maintain Approval of Avastin + Paclitaxel for Metastatic Breast Cancer
March 14, 2011
- New Task Force to Be Created for Reform of Pharmaceutical Regulations
March 14, 2011
- Restriction on Use of Multiple Drugs in the Elderly Needs Careful Review: Dr Adachi
March 14, 2011
- JPMA Introduces GL for Disclosure of Funds Provided to Healthcare Professionals
March 14, 2011
- Terumo to Launch DuraHeart in April
March 14, 2011
- Zyprexa Applied for Depressive Symptoms Associated with Bipolar Disorders
March 14, 2011
- Terumo's Drug-eluting Stent Recommended for Approval
March 14, 2011
- Warfarin Approved for Pediatric Use: Eisai
March 7, 2011
- Korosho Calls on Generic Firms to Apply for New Indications Based on Data from Public Domain
March 7, 2011
- HbA1c to Be Reported in Int'l Units from April 2012 at the Earliest
March 7, 2011
- Higher Dose of Finibax Recommended for Approval
March 7, 2011
- 5 Brands of New Class 1 OTC Drugs Recommended for Approval
March 7, 2011
- Merck Serono Aims to Increase Market Share for Saizen
March 7, 2011
- Chuikyo to Weigh Premium-Derived Profits, Cost of Development of Unapproved Drugs
March 7, 2011
- Fuji Pharma to Join JGA
March 7, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…